GH logo

GUARDANT HEALTH INC

GHNASDAQ
๐Ÿ† #515 by market capEarnings Feb 18US Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track GH
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$19.73B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
41.7%
High Growth
๐Ÿ“ŠGross Margin
65.2%
High
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
15.3x
Expensive
Otter Score
64
Fair
No chart data available for GH.

Trading Snapshot

Day Range
โ€”
52-Week Range
$74.55 โ€“ $191.05
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
134.2M
Next Earnings
2027-02-18

Fundamentals Snapshot

Annual Revenue
$982M
Last Q Revenue
$361M
P/E Ratio
โ€”
P/S Ratio
15.3x
EPS (TTM)
$-3.68
Dividend Yield
โ€”
Dilution (1yr)
+4.0%
GH logo

GUARDANT HEALTH INC

GH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$982Mโ–ฒ +32.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.5%โ–ฒ +6.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$437Mโ–ผ โˆ’1.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$233Mโ–ผ โˆ’15.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
128.7Mโ–ฒ +4.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$1.3Bโ–ผ โˆ’$521M YoY
StockOtter ยท stockotter.space

About GUARDANT HEALTH INC

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
64/100
Analyst data unavailable.

Latest News & Updates

MarketBeatยท14h ago

Guardant Health Sees Shield Coverage Boost in 2027, Holds Cash Flow Break-Even Target

Guardant Health NASDAQ: GH expects expanded insurance coverage for its Shield screening test and continued growth in its cancer testing portfolio to support its business in 2027, while maintaining a target of reaching fr

Business Wireยท3d ago

Guardant Health Launches Guardant Revealยฎ Ultra to Deliver Leading Sensitivity in MRD Testing

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. clinical launch of Guardant Revealยฎ Ultra, a new molecular residual disease (MRD) pla

Business Wireยท9d ago

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 13, 2026, the Compensation Committee of Guardant's Board of Directors approved

Business Wireยท10d ago

Guardant Health Prices $500 Million Convertible Senior Notes Offering

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (โ€œGuardant Healthโ€) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million aggregate principal am

Business Wireยท11d ago

Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (โ€œGuardant Healthโ€) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount o

Business Wireยท11d ago

Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360ยฎ Liquid

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360ยฎ Liquid designed to help oncologists understand how a patient